Showing 1 - 7 results of 7 for search 'Hamzah Abu-Sbeih', query time: 0.03s Refine Results
  1. 1
    Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment

    Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment by Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang

    Published 2019-05-01
    Get full text
    Article
  2. 2
    Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

    Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis by Hamzah Abu-Sbeih, Faisal S. Ali, Wenyi Luo, Wei Qiao, Gottumukkala S. Raju, Yinghong Wang

    Published 2018-09-01
    Get full text
    Article
  3. 3
    The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes

    The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes by Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang

    Published 2018-07-01
    Get full text
    Article
  4. 4
    Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

    Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study by Hamzah Abu-Sbeih, Faisal S. Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo, Zimu Gong, David M. Richards, Aline Charabaty, Yinghong Wang

    Published 2018-12-01
    Get full text
    Article
  5. 5
    Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort

    Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort by Sydney Pomenti, Cassandra Gandle, Hamzah Abu Sbeih, Meaghan Phipps, Alexandra Livanos, Averill Guo, Jonathan Yeh, Heather Burney, Hao Liu, Lara Dakhoul, Carla Kettler, Samer Gawrieh, Andrew deLemos, Andrew Scanga, Naga Chalasani, Ethan Miller, Julia Wattacheril

    Published 2020-11-01
    Get full text
    Article
  6. 6
    Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

    Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis by Wei Qiao, John A Thompson, Hamzah Abu-Sbeih, Yinghong Wang, Michael Dougan, Mehmet Altan, Michael A Postow, Yousef R Badran, Fangwen Zou, Anusha S Thomas, Sienna M Durbin, Barbara E Dutra, Donna E Leet, Po-Ying Lai, Nora K Horick, David M Faleck

    Published 2023-06-01
    Get full text
    Article
  7. 7
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events by Rajeev Sharma, Laura C Cappelli, Michelle Turner, Julie R Brahmer, Jarushka Naidoo, Paolo Antonio Ascierto, Igor Puzanov, Hamzah Abu-Sbeih, Jeffrey A Sosman, Marc S Ernstoff, Jill Brufsky, Mario E Lacouture, Douglas B Johnson, Lamya Hamad, Miguel-Angel Perales, Eric Hansen, David E Gerber, Frank B Cortazar, Gregory A Masters, Michele Nanni, Satish P Shanbhag, Dimitra Skondra

    Published 2021-06-01
    Get full text
    Article

Search Tools: